UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Treatment and prognosis of pulmonary veno-occlusive disease in adults

Authors
Jess Mandel, MD
Barbara LeVarge, MD
Section Editor
Scott Manaker, MD, PhD
Deputy Editor
Geraldine Finlay, MD

INTRODUCTION

Pulmonary veno-occlusive disease (PVOD) is a rare condition that represents a subgroup of patients with pulmonary hypertension (table 1). In general, PVOD progresses rapidly such that early recognition and treatment of this entity is critical.

The approach to treating patients with PVOD varies from center to center. Our approach is reviewed in this topic. Issues related to the epidemiology, pathogenesis, clinical features, and diagnosis of PVOD as well as the diagnosis and management of pulmonary arterial hypertension are discussed separately. (See "Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease in adults" and "Overview of pulmonary hypertension in adults" and "Clinical features and diagnosis of pulmonary hypertension in adults" and "Treatment of pulmonary hypertension in adults".)

GENERAL PRINCIPLES

All patients with a clinical or histopathologic diagnosis of pulmonary veno-occlusive disease (PVOD) should be managed in centers with expertise in pulmonary arterial hypertension (PAH). Details regarding diagnosis of PVOD are provided separately. (See "Epidemiology, pathogenesis, clinical evaluation, and diagnosis of pulmonary veno-occlusive disease in adults", section on 'Evaluation and approach to clinical diagnosis'.).

The approach used by most experts is based upon data derived from small case series of patients with PVOD-associated pulmonary hypertension as well as data extrapolated from larger randomized trials performed in patients with PAH. While considerable variation exists among centers, we suggest that the principles of managing patients with PVOD-associated pulmonary hypertension closely parallel that for patients with PAH (algorithm 1 and table 2). However, the clinician should be aware of important differences and potential harms of therapy that can occur in patients with PVOD (algorithm 2):

General measures – Patients with PVOD should receive routine conventional therapies (eg, oxygen, diuretic, vaccination) but are thought to be at greater risk of alveolar hemorrhage such that, as a general measure, routine anticoagulation is avoided by some experts. (See 'Conventional therapies' below and 'Anticoagulants' below.)

                           

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon May 16 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Rabiller A, Jaïs X, Hamid A, et al. Occult alveolar haemorrhage in pulmonary veno-occlusive disease. Eur Respir J 2006; 27:108.
  2. Montani D, Achouh L, Dorfmüller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87:220.
  3. Holcomb BW Jr, Loyd JE, Ely EW, et al. Pulmonary veno-occlusive disease: a case series and new observations. Chest 2000; 118:1671.
  4. Salzman GA, Rosa UW. Prolonged survival in pulmonary veno-occlusive disease treated with nifedipine. Chest 1989; 95:1154.
  5. Palevsky HI, Pietra GG, Fishman AP. Pulmonary veno-occlusive disease and its response to vasodilator agents. Am Rev Respir Dis 1990; 142:426.
  6. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62:D60.
  7. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37:67.
  8. Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report. Chest 2014; 146:449.
  9. Barboza CE, Jardim CV, Hovnanian AL, et al. Pulmonary veno-occlusive disease: diagnostic and therapeutic alternatives. J Bras Pneumol 2008; 34:749.
  10. Ye XQ, Yan CS, Zhang XY, et al. Lengthy diagnostic challenge in a rare case of pulmonary veno-occlusive disease: case report and review of the literature. Intern Med 2011; 50:1323.
  11. Barreto AC, Franchi SM, Castro CR, Lopes AA. One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. Braz J Med Biol Res 2005; 38:185.
  12. Kuroda T, Hirota H, Masaki M, et al. Sildenafil as adjunct therapy to high-dose epoprostenol in a patient with pulmonary veno-occlusive disease. Heart Lung Circ 2006; 15:139.
  13. Creagh-Brown BC, Nicholson AG, Showkathali R, et al. Pulmonary veno-occlusive disease presenting with recurrent pulmonary oedema and the use of nitric oxide to predict response to sildenafil. Thorax 2008; 63:933.
  14. Montani D, Jaïs X, Dorfmuller P, et al. Goal-oriented therapy in pulmonary veno-occlusive disease: a word of caution. Eur Respir J 2009; 34:1204.
  15. Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113:237.
  16. Okumura H, Nagaya N, Kyotani S, et al. Effects of continuous IV prostacyclin in a patient with pulmonary veno-occlusive disease. Chest 2002; 122:1096.
  17. Montani D, Jaïs X, Price LC, et al. Cautious epoprostenol therapy is a safe bridge to lung transplantation in pulmonary veno-occlusive disease. Eur Respir J 2009; 34:1348.
  18. Ogawa A, Miyaji K, Yamadori I, et al. Safety and efficacy of epoprostenol therapy in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. Circ J 2012; 76:1729.
  19. Matsushita K, Kanna M, Yazawa T, et al. Long-term survivor with pulmonary veno-occlusive disease. Circulation 2012; 125:e503.
  20. Bailey CL, Channick RN, Auger WR, et al. "High probability" perfusion lung scans in pulmonary venoocclusive disease. Am J Respir Crit Care Med 2000; 162:1974.
  21. Hoeper MM, Eschenbruch C, Zink-Wohlfart C, et al. Effects of inhaled nitric oxide and aerosolized iloprost in pulmonary veno-occlusive disease. Respir Med 1999; 93:62.
  22. Cassart M, Gevenois PA, Kramer M, et al. Pulmonary venoocclusive disease: CT findings before and after single-lung transplantation. AJR Am J Roentgenol 1993; 160:759.
  23. Kramer MR, Estenne M, Berkman N, et al. Radiation-induced pulmonary veno-occlusive disease. Chest 1993; 104:1282.
  24. Stewart S, McNeil K, Nashef SA, et al. Audit of referral and explant diagnoses in lung transplantation: a pathologic study of lungs removed for parenchymal disease. J Heart Lung Transplant 1995; 14:1173.
  25. Wille KM, Sharma NS, Kulkarni T, et al. Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation. Ann Am Thorac Soc 2014; 11:1411.
  26. Izbicki G, Shitrit D, Schechtman I, et al. Recurrence of pulmonary veno-occlusive disease after heart-lung transplantation. J Heart Lung Transplant 2005; 24:635.
  27. Takahashi K, Chen F, Ikeda T, et al. Single-lobe lung transplantation for rapidly deteriorating pulmonary venoocclusive disease. Ann Thorac Surg 2013; 95:689.
  28. Masters K, Bennett S. Pulmonary veno-occlusive disease: an uncommon cause of pulmonary hypertension. BMJ Case Rep 2013; 2013.
  29. Naniwa T, Takeda Y. Long-term remission of pulmonary veno-occlusive disease associated with primary Sjögren's syndrome following immunosuppressive therapy. Mod Rheumatol 2011; 21:637.
  30. Jones RM, Dawson A, Jenkins GH, et al. Sarcoidosis-related pulmonary veno-occlusive disease presenting with recurrent haemoptysis. Eur Respir J 2009; 34:517.
  31. Sanderson JE, Spiro SG, Hendry AT, Turner-Warwick M. A case of pulmonary veno-occlusive disease respondong to treatment with azathioprine. Thorax 1977; 32:140.
  32. De Vries TW, Weening JJ, Roorda RJ. Pulmonary veno-occlusive disease: a case report and a review of therapeutic possibilities. Eur Respir J 1991; 4:1029.
  33. Hackman RC, Madtes DK, Petersen FB, Clark JG. Pulmonary venoocclusive disease following bone marrow transplantation. Transplantation 1989; 47:989.
  34. Gilroy RJ Jr, Teague MW, Loyd JE. Pulmonary veno-occlusive disease. Fatal progression of pulmonary hypertension despite steroid-induced remission of interstitial pneumonitis. Am Rev Respir Dis 1991; 143:1130.
  35. Hoopes CW, Gurley JC, Zwischenberger JB, Diaz-Guzman E. Mechanical support for pulmonary veno-occlusive disease: combined atrial septostomy and venovenous extracorporeal membrane oxygenation. Semin Thorac Cardiovasc Surg 2012; 24:232.
  36. Strueber M, Hoeper MM, Fischer S, et al. Bridge to thoracic organ transplantation in patients with pulmonary arterial hypertension using a pumpless lung assist device. Am J Transplant 2009; 9:853.
  37. Richardson PG, Elias AD, Krishnan A, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92:737.
  38. Abecasis MM, Conceição Silva JP, Ferreira I, et al. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23:843.
  39. Willems E, Canivet JL, Ghaye B, et al. Pulmonary veno-occlusive disease in myeloproliferative disorder. Eur Respir J 2009; 33:213.
  40. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208114lbl.pdf (Accessed on April 07, 2016).
  41. Overbeek MJ, van Nieuw Amerongen GP, Boonstra A, et al. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J 2008; 32:232.
  42. Kataoka M, Yanagisawa R, Fukuda K, et al. Sorafenib is effective in the treatment of pulmonary veno-occlusive disease. Cardiology 2012; 123:172.
  43. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010; 182:1171.
  44. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013; 127:1128.
  45. Koiwa H, Tsujino I, Ikeda D, et al. An autopsy case of pulmonary veno-occlusive disease refractory to imatinib. Eur Respir J 2011; 37:968.
  46. Shackelford GD, Sacks EJ, Mullins JD, McAlister WH. Pulmonary venoocclusive disease: case report and review of the literature. AJR Am J Roentgenol 1977; 128:643.
  47. Cohn RC, Wong R, Spohn WA, Komer M. Death due to diffuse alveolar hemorrhage in a child with pulmonary veno-occlusive disease. Chest 1991; 100:1456.
  48. Justo RN, Dare AJ, Whight CM, Radford DJ. Pulmonary veno-occlusive disease: diagnosis during life in four patients. Arch Dis Child 1993; 68:97.